Loading..
  • SynAct Pharma logoSVE
  • SynAct Pharma logoENG
  • About us
    • The Company in brief
    • Vision
    • History
    • Organisation
    • New Partnerships
  • Our Science
    • Resolving Inflammation
    • Selective Melanocortin Stimulation
    • Scientific Advisory Board
  • Pipeline
    • Pipeline Overview
    • The AP1189 Development Program
    • Rheumatoid Arthritis
    • Membranous Nephropathy
    • Virus Induced Respiratory Insufficiency
    • Ongoing clinical studies
  • Investors
    • Listing Nasdaq 2022
    • Rights Issue 2022
    • Word from the CEO
    • Financial Reports
    • Investment highlights
    • Presentations
    • The Share
      • Share price development
      • Ownership Structure
      • Insiders
      • Share Capital Development
    • Analyst Coverage
    • Calendar
    • Press Releases
    • Prospectuses
  • Governance
    • General Meetings
    • Corporate Governance Report
    • Nomination Committee
      • Nomination Committee 2023
    • Board of Directors
      • Remuneration Committee
      • Audit Committee
    • Management
    • Auditor
    • Articles of Association
    • Code of Conduct
  • Media
    • Press Releases
    • Synact in Media
    • Image Bank
    • Subscribe
  • Contact

Press Releases

All releases
    • Regulatory
    • Non Regulatory
2016
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • All years
December 9, 2016
Non Regulatory

SynAct Pharma submits application for start of Phase I clinical study

November 28, 2016
Non Regulatory

SynAct Pharma recruits specialists for the early clinical studies

November 4, 2016
Non Regulatory

Interim report 3, 2016

October 28, 2016
Non Regulatory

SynAct Pharma fulfilled its commitments to the financier Seed Fund CapNova by a one-time payment

August 31, 2016
Non Regulatory

Half-yearly Report 2016

July 11, 2016
Non Regulatory

Trading starts in SynAct Pharma AB’s shares and subscription options on Aktietorget today

July 4, 2016
Non Regulatory

Market Announcement 174/16 – SynAct Pharma AB listed on Aktietorget 11 July 2016 – corrected version

June 14, 2016
Non Regulatory

SynAct Pharma AB’s issue before listing oversubscribed

June 3, 2016
Non Regulatory

Publication of additional prospectus

May 30, 2016
Non Regulatory

Bulletin from the Extraordinary General Meeting of SynAct Pharma AB (publ)

May 24, 2016
Non Regulatory

Today the subscription period for SynAct Pharma AB’s issue opens, before the planned listing on Aktietorget

May 24, 2016
Non Regulatory

Publication of SynAct Pharma AB’s prospectus in connection with the issue ahead of planned listing on Aktietorget

May 12, 2016
Non Regulatory

Notice of Extraordinary General Meeting of SynAct Pharma AB (publ)

May 9, 2016
Non Regulatory

Bulletin from the Extraordinary General Meeting of SynAct Pharma AB (publ)

April 21, 2016
Non Regulatory

Notice of Extraordinary General Meeting of SynAct Pharma AB (publ)

  • Media
    • Press Releases
    • Synact in Media
    • Image Bank
    • Subscribe

About Synact Pharma

SynAct Pharma is a clinical stage biotechnology company focused on resolving inflammation with melanocortin biology. Selective activation of the melanocortin system can help the immune system resolve excessive or chronic inflammation.

  • Privacy Policy
  • Cookies

Explore our Website

  • About us
  • Our Science
  • Pipeline
  • Investors
  • Governance
  • Media
  • Contact
  • LinkedIn

Subscribe